Compare BioNano Genomics Inc (BNGO) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Hyatt Hotels Corporation — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Hyatt Hotels Corporation trades at $189.7 (market cap $17.86B). The key difference: Hyatt Hotels Corporation is far larger — about 1353× BioNano Genomics Inc's market cap, and Hyatt Hotels Corporation pays a 0.32% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | H | |
|---|---|---|
Market Cap | $13.20M | $17.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $202.09 |
52-Week Low | $1.09 | $135.01 |
Enterprise Value | $15.81M | $21.71B |
Dividend Yield | — | 0.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Hyatt Hotels (H) trades at $184.72, down 3.36% in the last session, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company reported Q1 2026 EPS of $0.63, beating expectations, but faces profitability challenges with negative net income margins and ROE. Recent developments include expansion announcements and strategic investor presentations, while analyst consensus remains cautiously optimistic with a $198.20 price target.
Hyatt presents a growth opportunity through hotel expansion and premium positioning, but investors face risks from inconsistent profitability, rising debt levels, and economic sensitivity. The stock's valuation appears stretched with a P/E of 31.36, requiring strong execution on revenue growth and margin improvement to justify current levels amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
